The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Abstract
Objectives: The frontline drug doxorubicin has been used for treating cancer for over 30 years. While providing a cure in select cases, doxorubicin causes toxicity to most major organs, especially life-threatening cardiotoxicity, which forces the treatment to become dose-limiting. Key findings: Doxorubicin is known to bind to DNA-associated enzymes, intercalate with DNA base pairs, and target multiple molecular targets to produce a range of cytotoxic effects. For instance, it causes the activation of various molecular signals from AMPK (AMP-activated protein kinase inducing apoptosis) to influence the Bcl-2/Bax apoptosis pathway. By altering the Bcl-2/Bax ratio, downstream activation of different caspases can occur resulting in apoptosis. Doxorubicin also induces apoptosis and necrosis in healthy tissue causing toxicity in the brain, liver, kidney and heart. Over the years, many studies have been conducted to devise a drug delivery system that would eliminate these adverse affects including liposomes, hydrogel and nanoparticulate systems, and we highlight the pros and cons of these drug delivery systems. Summary: Overall the future for the continued use of doxorubicin clinically against cancer looks set to be prolonged, provided certain enhancements as listed above are made to its chemistry, delivery and toxicity. Increased efficacy depends on these three aims being met satisfactorily as discussed in turn in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cao, C., Lü, S., Kivlin, R., Wallin, B., Card, E., Bagdasarian, A., Tamakloe, T., Chu, W., Guan, K., & Wan, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804144200 · Cited by 113
RetractedBcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
Oltval, Z. N., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)90509-o · Cited by 6,003
The Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Bcl-2 and the regulation of programmed cell death
Reed, J. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.1.1 · Cited by 2,305
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
Doxorubicin: The good, the bad and the ugly effect
Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803312 · Cited by 1,509 · cited 6×
“Other side effects of extravasation include cellulitis, thrombophlebitis and joint movement limitation as a result of painful induration (pathological hardening of tissue).([7])”
BackgroundInfluentialChatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010) · Cardiology · doi:10.1159/000265166 · Cited by 1,065
Croce, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072367 · Cited by 1,055
Rules for Making Human Tumor Cells
Hahn, W. C., & Weinberg, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra021902 · Cited by 951
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Kunath, K. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00076-2 · Cited by 809
Anthrazykline in der Krebstherapie: Ein Überblick
Hortobágyi, G. N. (1997) · Drugs · doi:10.2165/00003495-199700544-00003 · Cited by 678
Liposome application: problems and prospects.
Barenholz, Y. (2001) · Current Opinion in Colloid & Interface Science · doi:10.1016/s1359-0294(00)00090-x · Cited by 659 · cited 1×
“To prevent initial drug leakage the lipid bilayer composition itself is altered, in conjunction with protocol changes to drug loading to stabilise the liposome’s ability to contain the drug effectively.([74,75]) Liposomes were soon coated with polyethylene glycol (PEG) to prolong circulation time.”
BackgroundMitra, S., Gaur, U., Ghosh, P. C., & Maitra, A. N. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00342-x · Cited by 647
Juliano, R. L., & Stamp, D. (1975) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(75)80433-5 · Cited by 522
Hayashi, T., Hirshman, M. F., Fujii, N., Habinowski, S. A., Witters, L. A., & Goodyear, L. J. (2000) · Diabetes · doi:10.2337/diabetes.49.4.527 · Cited by 447
p53-Dependent apoptosis pathways
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)82002-9 · Cited by 418
Terai, K., Hiramoto, Y., Masaki, M., Sugiyama, S., Kuroda, T., Hori, M., Kawase, I., & Hirota, H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9554-9575.2005 · Cited by 352
Imamura, K., Ogura, T., Kishimoto, A., Kaminishi, M., & Esumi, H. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5627 · Cited by 344
Progressive adriamycin nephropathy in mice: Sequence of histologic and immunohistochemical events
Wang, Y., Wang, Y. P., Tay, Y.-C., & Harris, D. C. H. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00342.x · Cited by 326
Poste, G. H., Bucana, C. D., Raz, A., Bugelski, P. J., Kirsh, R. L., & Fidler, I. J. (1982) · PubMed · Cited by 309
Płusa, T. (2012) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2012.1.1 · Cited by 298
Okoshi, R., Ozaki, T., Yamamoto, H., Ando, K., Koida, N., Ono, S., Koda, T., Kamijo, T., Nakagawara, A., & Kizaki, H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705232200 · Cited by 277
Liu, J., Mao, W., Ding, B., & Liang, C.-S. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00407.2008 · Cited by 255
Xiang, X., Saha, A. K., Wen, R., Ruderman, N. B., & Luo, Z. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.06.133 · Cited by 251
Adriamycin-induced, TNF-α-mediated central nervous system toxicity
Tangpong, J., Cole, M. P., Sultana, R., Joshi, G., Estus, S., Vore, M., St. Clair, W., Ratanachaiyavong, S., St. Clair, D. K., & Butterfield, D. A. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.013 · Cited by 238
Guo, D., Hildebrandt, I. J., Prins, R. M., Soto, H., Mazzotta, M. M., Dang, J., Czernin, J., Shyy, J. Y.-J., Watson, A. D., Phelps, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906606106 · Cited by 232
Mechanisms and management of doxorubicin cardiotoxicity
Shi, Y., Moon, M., Dawood, S., McManus, B., & Liu, P. P. (2011) · Herz · doi:10.1007/s00059-011-3470-3 · Cited by 215
Cullis, P. R., Hope, M. J., Bally, M. B., Madden, T. D., Mayer, L. D., & Fenske, D. B. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/s0304-4157(97)00006-3 · Cited by 212
Meisse, D., Van de Casteele, M., Beauloye, C., Hainault, I., Kefas, B. A., Rider, M. H., Foufelle, F., & Hue, L. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03110-1 · Cited by 205
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs
Danesi, R., Fogli, S., Gennari, A., Conte, P., & Del Tacca, M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241060-00004 · Cited by 203
Kim, Y., Ma, A.-G., Kitta, K., Fitch, S. N., Ikeda, T., Ihara, Y., Simon, A. R., Evans, T., & Suzuki, Y. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.368 · Cited by 188
Vail, D. M., Amantea, M. A., Colbern, G. T., Martin, F. J., Hilger, R. A., & Working, P. K. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.002 · Cited by 187
Characterization of a novel metabolic strategy used by drug‐resistant tumor cells
Harper, M., Antoniou, A., Villalobos‐Menuey, E., Russo, A., Trauger, R., Vendemelio, M., George, A., Bartholomew, R., Carlo, D., Shaikh, A., et al. (2002) · The FASEB Journal · doi:10.1096/fj.02-0541com · Cited by 172
A role for ceramide in driving cancer cell resistance to doxorubicin
Liu, Y., Yu, J. Y., Yin, D., Patwardhan, G. A., Gupta, V. K., Hirabayashi, Y., Holleran, W. M., Giuliano, A. E., Jazwinski, S. M., Gouazé‐Andersson, V., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-092981 · Cited by 170
Cognitive effects of chemotherapy in post‐menopausal breast cancer patients 1 year after treatment
Collins, B., Mackenzie, J., Stewart, A., Bielajew, C., & Verma, S. (2009) · Psycho-Oncology · doi:10.1002/pon.1379 · Cited by 168
Kefas, B., Cai, Y., Ling, Z., Heimberg, H., Hue, L., Pipeleers, D., & Van de Casteele, M. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0300151 · Cited by 163
Pifithrin-α protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice
Liu, X., Chua, C. C., Gao, J., Chen, Z., Landy, C. L. C., Hamdy, R., & Chua, B. H. L. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00759.2003 · Cited by 162
Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review
Lal, S., Mahajan, A., Chen, W. N., & Chowbay, B. (2010) · Current Drug Metabolism · doi:10.2174/138920010791110890 · Cited by 154
Jansen, C. E., Dodd, M. J., Miaskowski, C. A., Dowling, G. A., & Kramer, J. H. (2008) · Psycho-Oncology · doi:10.1002/pon.1342 · Cited by 146
Ta, H. T., Dass, C. R., Larson, I. C., Choong, P., & Dunstan, D. E. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.03.022 · Cited by 144
Self-citationPhoto-induced cytotoxicity of malonic acid [C60]fullerene derivatives and its mechanism
Yang, X., Fan, C., & Zhu, H. (2002) · Toxicology in Vitro · doi:10.1016/s0887-2333(01)00102-3 · Cited by 135
Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs
Ashley, N., & Poulton, J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.059 · Cited by 134
ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial Genome
Elliott, A. M., & Al‐Hajj, M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0235 · Cited by 127
Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury
Sakata, Y., Dong, J.-W., Vallejo, J. G., Huang, C., Baker, J. S., Tracey, K. J., Tacheuchi, O., Akira, S., & Mann, D. L. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00642.2006 · Cited by 122
Involvement of AMPK Signaling Cascade in Capsaicin‐Induced Apoptosis of HT‐29 Colon Cancer Cells
KIM, Y. M., Hwang, J., KWAK, D. W., Lee, Y. K., & Park, O. J. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1397.053 · Cited by 120
5′-aminoimidazole-4-carboxamide riboside induces apoptosis in human neuroblastoma cells
Garcia‐Gil, M., Pesi, R., Perna, S., Allegrini, S., Giannecchini, M., Camici, M., & Tozzi, M. G. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00836-9 · Cited by 112
Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma
Huang, J. X., Liu, K., Yu, Y. P., et al. (2012) · Autophagy · doi:10.4161/auto.8.2.18940 · Cited by 111
Cummings, J., & McArdle, C. (1986) · British Journal of Cancer · doi:10.1038/bjc.1986.141 · Cited by 109
THE HEPATIC PHARMACOKINETICS OF DOXORUBICIN AND LIPOSOMAL DOXORUBICIN
Hilmer, S. N., Cogger, V. C., Muller, M., & Couteur, D. G. L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.794 · Cited by 99
Shin, S. M., & Kim, S. G. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.051128 · Cited by 89
Chen, M., Shen, W., Yang, Y., Wu, X., Gu, J., & Lu, P. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22522 · Cited by 88
AMPK mediates curcumin-induced cell death in CaOV3 ovarian cancer cells
Di (1994) · Oncology Reports · doi:10.3892/or_00000179 · Cited by 83
McGahon, A. J., Costa‐Pereira, A. P., Daly, L., & Cotter, T. G. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00745.x · Cited by 81
Compound K Induces Apoptosis via CAMK-IV/AMPK Pathways in HT-29 Colon Cancer Cells
Kim, D. Y., Park, M. W., Yuan, H. D., Lee, H., Kim, S. H., & Chung, S. H. (2009) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf902700h · Cited by 81
Kubo, T., Sugita, T., Shimose, S., Nitta, Y., Ikuta, Y., & Murakami, T. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.1.121 · Cited by 79
Tan, M. L., Friedhuber, A. M., Dunstan, D. E., Choong, P., & Dass, C. R. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.069 · Cited by 75
Self-citationAdriamycin-activated macrophages as tumor growth inhibitors.
Js, H. (1981) · PubMed · Cited by 69
Pegylated Liposomal Doxorubicin
Plosker, G. L. (2008) · Drugs · doi:10.2165/0003495-200868170-00008 · Cited by 54
An Ancestral Haplotype Defines Susceptibility to Doxorubicin Nephropathy in the Laboratory Mouse
Zheng, Z., Pavlidis, P., Chua, S. C., D’Agati, V. D., & Gharavi, A. G. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121373 · Cited by 53
Sun, K., Wang, J., Zhang, J., Hua, M., Liu, C., & Chen, T. (2011) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2011.04.007 · Cited by 52
Mechanism of anthracycline-mediated down-regulation of GATA4 in the heart
Park, A.-M., Nagase, H., Liu, L., Kumar, S. V., Szwergold, N. R., Wong, C., & Suzuki, Y. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq361 · Cited by 47
Itokazu, M., Kumazawa, S., Wada, E., & Wenyi, Y. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04337-6 · Cited by 36
Liu, J., Tu, D., Dancey, J. E., Reyno, L. M., Pritchard, K. I., Pater, J. L., & Seymour, L. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9257-1 · Cited by 34
Lee, Y. M., Uhm, K.-O., Lee, E. S., Kwon, J. S., Park, S. H., & Kim, H. S. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.003 · Cited by 24
Oncogenes as Novel Targets for Cancer Therapy (Part IV): Regulators of the Cell Cycle and Apoptosis
Zhang, Z., Li, M., Rayburn, E. R., Hill, D. L., Zhang, R., & Wang, H. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505060-00006 · Cited by 22
Oncogenes as Novel Targets for Cancer Therapy (Part III): Transcription Factors
Zhang, Z., Li, M., Rayburn, E. R., Hill, D. L., Zhang, R., & Wang, H. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505050-00005 · Cited by 12
Cited by
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683
DNA Nanotechnology-Enabled Drug Delivery Systems
Hu, Q., Li, H., Wang, L., Gu, H., & Fan, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00663 · Cited by 1,118
Cu-Catalyzed Click Reaction in Carbohydrate Chemistry
Tiwari, V. K., Mishra, B. B., Mishra, K. B., Mishra, N., Singh, A. S., & Chen, X. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00408 · Cited by 862
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Metadata
- Authors
- Tacar, O., Sriamornsak, P., & Dass, C. R.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-01
- Volume
- 65
- Issue
- 2
- Pages
- 157-170
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W1543790510
- Cited by
- 2,465
- References
- 74
- FWCI
- 41.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.